Join us for 13th HTAsiaLink 2026, “A Step Forward – Powering Policy Impact with HTA in Asia,” highlights steady progress—step by step—toward stronger systems, deeper evidence, and more responsive decisions. Together, we’re shaping a more impactful future for HTA in Asia.

The Center for Drug Evaluation (CDE) was established by the Department of Health (now the Ministry of Health and Welfare, MOHW) on July 13th, 1998. The purpose of the CDE is to enhance the quality and efficiency of the evaluation of drugs and medical devices, further guaranteeing the public drug safety and increasing the public access to safe, effective and innovative drugs and medical devices.

The CDE’s consultation services are available to the biotech companies, pharmaceutical companies, non-government organization and research institutes registered in Taiwan. Foreign companies or academic research institutes seeking the CDE’s consultation services should send their requests through any of the aforementioned eligible agencies in Taiwan.